On July 18, 2023, Harrow Health, Inc. modified a credit agreement with Oaktree Fund Administration, LLC, expanding the overall loan size from $100 million to $112.5 million to finance the recently acquired Santen Products and other corporate purposes. The total loan drawn will be $77.5 million with up to $35 million still available. Projected revenues are over $31 million and over $9.3 million of adjusted EBITDA for the period ending June 30, 2023. The company also completed the acquisition of commercial rights for the U.S. and Canadian markets of the ophthalmic drug, VEVYE, and certain other assets associated with Santen and Eyevance products.